Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 7876 AL 7890

Donanemab: The dawn of disease-modifying treatment for Alzheimer's disease in Australia

Loi SM, Kang MJ.

Australas Psychiatry. 2025 Aug;33(4):599-602. doi: 10.1177/10398562251355157. Epub 2025 Jun 23.

History repeats itself: A new trivializing term for a potentially life-threatening side effect of antibody Alzheimer's disease therapy

Høilund-Carlsen PF, Barrio JR.

J Alzheimers Dis. 2025 Aug;106(3):925-927. doi: 10.1177/13872877251350295. Epub 2025 Jun 19.

Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease

Rosen J, Jessen F.

J Prev Alzheimers Dis. 2025 Apr;12(4):100102. doi: 10.1016/j.tjpad.2025.100102. Epub 2025 Feb 25.

Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer's disease and a literature review

Wang Y, Yu Q, Chen B, Zhou J, Li Z, Liao W, Liu J, Yang A.

BMC Neurol. 2025 Jul 7;25(1):281. doi: 10.1186/s12883-025-04302-5.

Tolerability of rivastigmine transdermal patch in patients with Alzheimer's disease: a narrative review

García Ribas G, Ferrer-Picón E.

Expert Opin Drug Saf. 2026 Apr;25(4):643-655. doi: 10.1080/14740338.2025.2576520. Epub 2025 Oct 31.

VEGFB is a potential therapeutic target for Alzheimer's disease: Insights from integrative multi-omics analysis

Ye H, Zhuang C, Jin Z, Hu Y, He J, Yu Q, Hu H, Zheng Y.

J Alzheimers Dis. 2025 Dec;108(3):1073-1087. doi: 10.1177/13872877251385244. Epub 2025 Oct 17.

Efficacy and Safety of Natural Apigenin Treatment for Alzheimer's Disease: Focus on In vivo Research Advancements

Zhang N, Nao J, Dong X.

Curr Neuropharmacol. 2025;23(6):728-754. doi: 10.2174/1570159X23666241211095018.

Alzheimer's Disease May Benefit from Olive Oil Polyphenols: A Systematic Review on Preclinical Evidence Supporting the Effect of Oleocanthal on Amyloid-β Load

Zupo R, Castellana F, Panza F, Solfrizzi V, Lozupone M, Tardugno R, Cicero N, Corbo F, Crupi P, Sardone R, Clodoveo ML.

Curr Neuropharmacol. 2025;23(10):1249-1259. doi: 10.2174/011570159X327650241021115228.

Can ketamine therapy overcome treatment-resistant depression in Alzheimer's disease and older adults? Preclinical and clinical evidence

Mario A, Ivana L, Claudia MM, Antonello B, Francesco P, Tommaso C, Madia L.

Biomed Pharmacother. 2025 Jul;188:118199. doi: 10.1016/j.biopha.2025.118199. Epub 2025 May 23.

Mechanistic Population Pharmacokinetic-Pharmacodynamic Model of the Tau-Targeted Antibody Posdinemab in Healthy Participants and Participants with Alzheimer's Disease

Pérez-Ruixo C, Li L, Galpern WR, Perez-Ruixo JJ.

Clin Pharmacol Ther. 2026 Apr;119(4):979-989. doi: 10.1002/cpt.70173. Epub 2025 Dec 22.

Practical Brain MRI Guidelines for Anti-Aβ Antibody Treatment in Early Symptomatic Alzheimer's Disease

Kakeda S, Miki Y, Kudo K, Mori H, Tokumaru AM, Abe O, Aoki S; Working Group for Brain MRI Guidelines for Anti-Aβ Antibody Treatment from The Japan Radiological Society, The Japanese Society for Neuroradiology, and The Japanese Society for Magnetic Resonance in Medicine.

Magn Reson Med Sci. 2025 Nov 20;24(4):2025-1000. doi: 10.2463/mrms.gl.2025-1000. Epub 2025 Apr 5.

Randomized controlled trial of Bushen Yinao pill combined with conventional therapy on intestinal flora and cognitive function in older patients with Alzheimer's disease

Wang W, Zhang J, Li C.

Int J Psychiatry Med. 2025 May;60(3):280-295. doi: 10.1177/00912174241290962. Epub 2024 Dec 12.

Brain morphological characteristics predicting clinical response to selective serotonin reuptake inhibitors or cholinesterase inhibitors: A study of electronic medical records in patients with cognitive disorders

Onda K, Chotiyanonta JS, Cowley HP, Uchida Y, Nowrangi MA, Adams R, Lyketsos CG, Zandi PP, Oishi K.

Int Psychogeriatr. 2025 Dec;37(6):100105. doi: 10.1016/j.inpsyc.2025.100105. Epub 2025 Jun 25.

Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer Disease: Intersocietal Recommendations for Their Appropriate Use in Switzerland

Felbecker A, Felbecker A, Rouaud O, Lathuiliere A, Allali G, Sollberger M, Meyer-Heim T, Monsch AU, Lövblad KO, Becker S, Barro-Belaygues N, Popp J, Bürge M, Lindheimer K, Gietl A, Jung HH, Georgescu D, Meyer R, Frisoni GB.

Neurodegener Dis. 2025;25(3):114-125. doi: 10.1159/000545799. Epub 2025 Apr 14.

Financial Incentives to Increase Diversity of Older Participants in a Memory Concerns Registry: A Randomized Clinical Trial

Jacobson M, Molina-Henry D, Chang TY, Jimenez-Maggiora GA, Pramanik R, Shah SB, Aisen PS.

JAMA Health Forum. 2025 Aug 1;6(8):e252273. doi: 10.1001/jamahealthforum.2025.2273.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias